Fig. 2: HuR degradation causes anti-tumorigenic effects in vitro.
From: A TRIM21-based bioPROTAC highlights the therapeutic benefit of HuR degradation
A, B Representative immunoblot and associated densitometry of the parental HCT116 cell line and HCT116-ODIn cell lines (T21RBCC-VHHGFP, VHHHuR and T21RBCC-VHHHuR) at 72 h post doxycycline. C, D Representative immunoblot and associated densitometry of the doxycycline-inducible T21RBCC-VHHHuR cell line following 24 h with doxycycline and/or DMSO or 5 µM MG132. E Cell viability measured using the MTT assay by measuring relative absorbance (570 nm) of parental and ODIn-HCT116 cells at 72 h post doxycycline. F, G Representative images and bar graph of number of colonies formed by parental and ODIn-HCT116 cells at 8 days post doxycycline in a colony formation assay. Data in B (n = 3), D (n = 4), E (n = 4) and G (n = 3) show the mean and standard deviation from biologically independent samples per group, as outlined. Statistical significance was calculated using a one-way ANOVA and post-hoc test. Source data are provided as a Source Data file.
